HELP THE PHILLY PI DELIVER UNBIASED, COMMUNITY-FOCUSED NEWS
The Philly PI relies on reader support to deliver crucial investigative reporting, breaking news, community safety updates, and transparent tech coverage. Independent journalism requires time, deep research, and absolute editorial freedom—free from paywalls, political influence, or corporate control. We cannot keep our newsroom running without you.
100% READER-FUNDED NEWSROOM
NO PAYWALLS OR CORPORATE CONTROL
KEEP INDEPENDENT JOURNALISM FREE FOR ALL
Credit: Unsplash. Snakebite may be killing far more people than anyone realized.…
Mpox is back in the headlines, again. Ten confirmed cases in Guinea-Bissau…
Most of the jars are carved from sandstone; others are made of…
Hermit crab. Image via Wiki Commons. In the humid, coastal forests of…
Flow in the Colorado River has shrunk by about 20% since 2000,…
For centuries, people along China’s rivers and coasts lashed bamboo together and…
RNAi-focused clinical-stage biotech City Therapeutics (CTY) has officially priced its upsized initial public offering at $18.00 per share, hitting the…
Iambic Therapeutics (IAM), a San Diego-based Phase 1 cancer biotechnology company, has priced its initial public offering at $16.00 per…
Biotechs Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are taking center stage this week as the only two…
Cambridge, Massachusetts-based clinical biotech firm City Therapeutics has set terms for its upcoming initial public offering on the NASDAQ under…
South San Francisco-based biotech firm TRex Bio (TRXB) has priced its initial public offering at $14.00 per share—the low end…
Sign in to your account